Place de l'hormonothérapie dans le traitement du cancer de prostate métastatique

25 novembre 2008

Auteurs : T. Lebret, A. Méjean
Référence : Prog Urol, 2008, 18, S332, suppl. S7
   
 
 

 

 
Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser

   

 

 
 
 

Références

 

Huggins C., Hodges C.V. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate 1941 J Urol 2002 ;  168 : 9-12 [cross-ref]
 
Huggins C., Hodges C.V. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate 1941 J Urol 2002 ;  167 : 948-951 [cross-ref]
 
Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy JAMA 1999 ;  281 : 1591-1597 [cross-ref]
 
Steers W.D. 5alpha-reductase activity in the prostate Urology 2001 ;  58 : 17-24 [inter-ref]
 
Rossi D., Tostain J. Déficit androgénique lié à l’âge et vieillissement masculin Rapport du congrès AFU 2004 Prog Urol 2004 ;  14 : 627-868
 
Schally A.V., Kastin A.J., Arimura A. Hypothalamic follicle-stimulating hormone (FSH) and luteinizing hormone (LH) -regulating hormone:structure, physiology, and clinical studies Fertil Steril 1971 ;  22 : 703-721 [cross-ref]
 
Schally A.V., Arimura A., Kastin A.J., Matsuo H., Baba Y., Redding T.W., et al. Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle stimulating hormones Science 1971 ;  173 : 1036-1038
 
Lebret T, Bouregba A. Roles of the urologist and nurse from the perspective of patients with prostate cancer receiving luteinizing hormone-releasing hormone analogue therapy. BJU Int. 2008 Jun 11.
 
Bouregba A., Lebret T. Le cancer de prostate, l’urologue, le patient et le traitement Ann Urol 2007 ;  41 : S87-91 [inter-ref]
 
Cox R.L., Crawford E.D. Estrogens in the treatment of prostate cancer J Urol 1995 ;  154 : 1991-1998 [cross-ref]
 
Tombal B. What is new in hormone therapy for prostate cancer Eur Urol 2008 ;  4 : 477-483 [cross-ref]
 
Parmar H., Edwards L., Phillips R.H., Allen L., Lightman S.L. Orchiectomy versus long-acting D-Trp-6-LHRH in advanced prostatic cancer Br J Urol 1987 ;  59 : 248-254 [cross-ref]
 
Turkes A.O., Peeling W.B., Griffiths K. Treatment of patients with advanced cancer of the prostate: phase III trial, zoladex against castration; a study of the British Prostate Group J Steroid Biochem 1987 ;  27 : 543-549 [cross-ref]
 
Soloway M.S., Chodak G., Vogelzang N.J., Block N.L., Schellhammer P.F., Smith J.A., et al. Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomised trial. Zoladex Prostate Study Group Urology 1991 ;  37 : 46-51 [cross-ref]
 
Botto H., Rouprêt M., Mathieu F., Richard F. Multicentre randomized trial comparing triptorelin medical castration versus surgical castration in the treatment of locally advanced or metastatic prostate cancer Prog Urol 2007 ;  17 : 235-239 [inter-ref]
 
Oefelein M.G., Feng A., Scolieri M.J., Ricchiutti D., Resnick M.I. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making Urology 2000 ;  56 : 1021-1024 [inter-ref]
 
Tombal B., Jasiensky S., Debie B., et al. Is there a significant difference in testosterone level after surgical castration, goserilin or triptorelin? Eur Urol Suppl 2007 ;  6 : 87abstract n ° 260.  [cross-ref]
 
Oefelein M.G., Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm J Urol 2000 ;  164 : 726-729 [cross-ref]
 
Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6,3 years of followup. J Urol 2000;164:1579-82.
 
Iversen P., Tyrrell C.J., Kaisary A.V., Anderson J.B., Van Poppel H., Tammela T.L., et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6, 3 years of followup J Urol 2000 ;  164 : 1579-1582 [cross-ref]
 
Labrie F., Dupont A., Belanger A., Lacoursiere Y., Raynaud J.P., Husson J.M., et al. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens Prostate 1983 ;  4 : 579-594 [cross-ref]
 
Labrie F., Dupont A., Giguere M., Borsanyi J.P., Belanger A., Lacourciere Y., et al. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer J Steroid Biochem 1986 ;  25 : 877-883 [cross-ref]
 
Laufer M., Denmeade S.R., Sinibaldi V.J., Carducci M.A., Eisenberger M.A. Complete androgen blockade for prostate cancer: what went wrong? J Urol 2000 ;  164 : 3-9 [cross-ref]
 
Maximum, rogen blockade in advanced prostate cancer: an overview of the randomised trials Prostate Cancer Trialists ‘Collaborative Group Lancet 2000 ;  355 : 1491-1498
 
Prostate Cancer Trialist’s Collaborative Group Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials Lancet 2000 ;  355 : 1491-1498
 
Isaacs J.T., Coffey D.S. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma Cancer Res 1981 ;  41 : 5070-5075
 
Bruchovsky N., Rennie P.S., Coldman A.J., Goldenberg S.L., To M., Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma Cancer Res 1990 ;  50 : 2275-2282
 
Akakura K., Bruchovsky N., Goldenberg S.L., Rennie P.S., Buckley A.R., Sullivan L.D. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen Cancer 1993 ;  71 : 2782-2790 [cross-ref]
 
Sato N., Gleave M.E., Bruchovsky N., Rennie P.S., Goldenberg S.L., Lange P.H., et al. Intermittent androgen suppression delays progression to androgen-independent regulation of prostatespecific antigen gene in the LNCaP prostate tumour model J Steroid Biochem Mol Biol 1996 ;  58 : 139-146 [cross-ref]
 
Buhler K.R., Santucci R.A., Royai R.A., Whitney S.C., Vessella R.L., Lange P.H., et al. Intermittent androgen suppression in the LuCaP 23 12 prostate cancer xenograft model Prostate 2000 ;  43 : 63-70 [cross-ref]
 
Trachtenberg J. Experimental treatment of prostatic cancer by intermittent hormonal therapy J Urol 1987 ;  137 : 785-788 [cross-ref]
 
Russo P., Liguori G., Heston W.D., Huryk R., Yang C.R., Fair W.R., et al. Effects of intermittent diethylstilbestrol diphosphate administration on the R3327 rat prostatic carcinoma Cancer Res 1987 ;  47 : 5967-5970
 
Peyromaure M., Zerbib M. Traitement intermittent du cancer de prostate Ann Urol 2005 ;  39 : 116-123 [inter-ref]
 
Goldenberg S.L., Bruchovsky N., Gleave M.E., Sullivan L.D., Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report Urology 1995 ;  45 : 839-844
 
Higano C.S., Ellis W., Russell K., Lange P.H. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study Urology 1996 ;  48 : 800-804 [inter-ref]
 
Hall M.C., Fritzsch R.J., Sagalowsky A.I., Ahrens A., Petty B., Roehrborn C.G. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer Urology 1999 ;  53 : 898-902discussion 902-3.  [inter-ref]
 
Nejat R.J., Rashid H.H., Bagiella E., Katz A.E., Benson M.C. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy J Urol 2000 ;  164 : 1891-1894 [cross-ref]
 
Crook J.M., Szumacher E., Malone S., Huan S., Segal R. Intermittent androgen suppression in the management of prostate cancer Urology 1999 ;  53 : 530-534 [inter-ref]
 
Bouchot O., Lenormand L., Karam G., Prunet D., Gaschignard N., Malinovsky J.M., et al. Intermittent androgen suppression in the treatment of metastatic prostate cancer Eur Urol 2000 ;  38 : 543-549 [cross-ref]
 
Kurek R., Renneberg H., Lübben G., Kienle E., Tunn U.W. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer Eur Urol 1999 ;  35 : 27-31 [cross-ref]
 
Sato N., Akakura K., Isaka S., Nakatsu H., Tanaka M., Ito H., et al. Chiba Prostate Study Group. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study Urology 2004 ;  64 : 341-345 [inter-ref]
 
Albrecht W., Collette L., Fava C., Kariakine O.B., Whelan P., Studer U.E., et al. Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study Eur Urol 2003 ;  44 : 505-511 [cross-ref]
 
Higano C., Shields A., Wood N., Brown J., Tangen C. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression Urology 2004 ;  64 : 1182-1186 [inter-ref]
 
Goldenberg S.L., Gleave M.E., Taylor D., Bruchovsky N. Clinical Experience with Intermittent Androgen Suppression in Prostate Cancer: Minimum of 3 Years’ Follow-Up Mol Urol 1999 ;  3 : 287-292
 
Hurtado-Coll A., Goldenberg S.L., Gleave M.E., Klotz L. Intermittent androgen suppression in prostate cancer: the Canadian experience Urology 2002 ;  60 : 52-56 [inter-ref]
 
Pether M., Goldenberg S.L. Intermittent androgen suppression BJU Int 2004 ;  93 : 258-261 [cross-ref]
 
Pether M., Goldenberg S.L., Bhagirath K., Gleave M. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience Can J Urol 2003 Apr ;  10 (2) : 1809-1814
 
De La Taille A., Zerbib M., Conquy S., Amsellem-Ouazana D., Thiounn N., Flam T.A., et al. Intermittent androgen suppression in patients with prostate cancer BJU Int 2003 ;  91 : 18-22 [cross-ref]
 
Prapotnich D., Fizazi K., Escudier B., Mombet A., Cathala N., Vallancien G. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer Eur Urol 2003 ;  43 : 233-239discussion 239-40.  [cross-ref]
 
Youssef E., Tekyi-Mensah S., Hart K., Bolton S., Forman J. Intermittent androgen deprivation for patients with recurrent metastatic prostatecancer Am J Clin Oncol 2003 ;  26 : e119-e123
 
de Leval J., Boca P., Yousef E., Nicolas H., Jeukenne M., Seidel L., et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naïve prostate cancer: results of a prospective randomized multicenter trial Clin Prostate Cancer 2002 ;  1 : 163-171 [cross-ref]
 
Wright J.L., Higano C.S., Lin D.W. Intermittent androgen deprivation: clinical experience and practical applications Urol Clin North Am 2006 ;  33 : 167-179 [inter-ref]
 
Miller J.I., Ahmann F.R., Drach G.W., Emerson S.S., Bottaccini M.R. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer J Urol 1992 ;  147 : 956-961 [cross-ref]
 
   
 
 
   

 

© 2008  Elsevier Masson SAS. Tous droits réservés.